Rankings
▼
Calendar
TARS Q4 2023 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
TARS
Tarsus Pharmaceuticals, Inc.
$3B
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$13M
+30.8% YoY
Gross Profit
$12M
90.7% margin
Operating Income
-$44M
-339.9% margin
Net Income
-$42M
-320.4% margin
EPS (Diluted)
$-1.31
QoQ Revenue Growth
+598.9%
Cash Flow
Operating Cash Flow
-$39M
Free Cash Flow
-$39M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$265M
Total Liabilities
$69M
Stockholders' Equity
$197M
Cash & Equivalents
$225M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$13M
$10M
+30.8%
Gross Profit
$12M
$10M
+23.5%
Operating Income
-$44M
-$15M
-195.1%
Net Income
-$42M
-$14M
-208.1%
Revenue Segments
Product
$13M
100%
← FY 2023
All Quarters
Q1 2024 →